Asia
Shanghai HeartCare Medical Expects H1 Profit to Rise
Shanghai HeartCare Medical Technology (HKG:6609) expects net profit for the first half of 2026 to reach at least 60 million yuan, up from 50.9 million yuan a year earlier, according to a Hong Kong bourse filing.The cardiac medical device maker attributed the profit growth mainly to increased sales of high-margin products.Revenue is expected to rise at least 50.9% to 280 million yuan from 185.5 million yuan, driven by broader product adoption, higher end-user demand and expanded hospital coverage.
HKG:6609
